Ketamine vs Traditional Antidepressants: How They Work, How Fast They Act, and Which May Be Right for Depression

Ketamine vs antidepressants is no longer a question limited to research laboratories. As ketamine-based treatments have moved into mainstream mental health discussions, more people with depression are asking how ketamine compares with familiar medications such as SSRIs and SNRIs.

The biggest difference is not simply how strong one treatment is compared with another. Ketamine and traditional antidepressants work through different biological pathways, have different timelines, different safety considerations, and different roles in depression treatment.

Traditional antidepressants such as SSRIs and SNRIs remain first-line treatments for many people with depression and have decades of clinical experience behind them. They are generally taken every day and may require several weeks before their full antidepressant effect becomes clear.

Ketamine, by contrast, can produce antidepressant effects much more rapidly in some people, particularly those with treatment-resistant depression. Research supported by the National Institute of Mental Health has found that ketamine can reduce depressive symptoms within hours in some patients, although response varies and ongoing treatment may be needed to maintain improvement.

For people who have already tried multiple antidepressants without adequate improvement, this difference in mechanism and speed can be especially important.

But does faster mean better?

Not necessarily.

The right treatment depends on the diagnosis, treatment history, symptom severity, medical history, preferences, access, cost, and the judgment of a qualified healthcare professional.

This guide explains the key differences between ketamine and traditional antidepressants so you can have a more informed conversation with your healthcare provider.

Ketamine vs Antidepressants at a Glance

Factor	Ketamine-Based Treatment	Traditional Antidepressants
Primary mechanism	Primarily involves glutamate/NMDA signaling and downstream neuroplasticity pathways	Commonly affects serotonin, norepinephrine, dopamine, or combinations of these systems
How quickly effects may begin	Often within hours to days in responsive patients	Commonly takes several weeks
Typical treatment pattern	Usually administered in a structured treatment course, depending on formulation	Usually taken daily
Most established role	Treatment-resistant depression and specific FDA-approved uses of esketamine	Broad range of depressive and anxiety disorders
FDA status	Ketamine itself is FDA-approved as an anesthetic; esketamine nasal spray is FDA-approved for specific depressive indications	Many individual antidepressants are FDA-approved for depression and/or other psychiatric conditions
Administration	Depends on formulation: IV, nasal, or other routes	Usually oral tablets or capsules
Common considerations	Dissociation, sedation, blood-pressure changes, dizziness and misuse potential require clinical screening and monitoring	Nausea, sleep changes, sexual side effects and discontinuation symptoms can occur
Long-term evidence	Growing, but less extensive than the decades of evidence for traditional antidepressants	Extensive long-term clinical experience
Best suited for	Carefully selected patients, particularly when conventional treatment has not provided sufficient benefit	Many people with depression, anxiety and related conditions

How Traditional Antidepressants Work

Traditional antidepressants have been the foundation of depression treatment for decades.

Common categories include:

• SSRIs, or selective serotonin reuptake inhibitors
• SNRIs, or serotonin-norepinephrine reuptake inhibitors
• NDRIs, such as bupropion
• Tricyclic antidepressants
• MAOIs
• Other medications used alone or as augmentation treatments

SSRIs and SNRIs are among the most commonly prescribed because they have substantial evidence supporting their use across several depressive and anxiety disorders.

These medications influence neurotransmitter signaling, particularly serotonin and/or norepinephrine. Their effects develop progressively rather than immediately.

According to the National Institute of Mental Health, antidepressants commonly take 4–8 weeks to work, although some symptoms may improve earlier.

That waiting period can be frustrating, particularly when someone is experiencing severe symptoms or has already tried several medications.

However, the slower onset does not make traditional antidepressants inferior.

They remain an important treatment option because they are:

• Well studied
• Widely available
• Generally affordable in generic forms
• Convenient for many patients
• Suitable for long-term treatment when effective
• Supported by decades of clinical experience

For someone beginning treatment for depression, an antidepressant may still be an appropriate starting point.

How Does Ketamine Work Differently?

Ketamine’s antidepressant effects involve a different biological system from conventional serotonin-based medications.

Ketamine primarily interacts with the glutamate system, including NMDA receptors. Research has linked this activity to downstream changes in neural signaling and neuroplasticity—the brain’s ability to modify and strengthen connections.

This is one reason ketamine has attracted significant attention in depression research.

Instead of waiting weeks for gradual changes associated with conventional antidepressant treatment, ketamine can produce measurable antidepressant effects much more quickly in some patients.

NIMH-supported research describes ketamine as a rapid-acting treatment that can lift depressive symptoms within hours in some people with treatment-resistant depression.

However, it is important to avoid a common misconception.

Ketamine does not simply “repair the brain” or permanently rewire depression after one treatment.

The neuroplasticity model is an important part of current research, but the clinical response is more complicated. Some people respond strongly, others respond partially, and some do not respond. Benefits may also fade without continued treatment or other forms of ongoing care.

That is why ketamine treatment should be viewed as part of a broader treatment plan rather than a guaranteed one-time cure.

Why Does Ketamine Work Faster Than SSRIs?

This is one of the most important differences between ketamine and traditional antidepressants.

SSRIs and SNRIs generally require time for their therapeutic effects to develop. NIMH notes that antidepressants commonly take 4–8 weeks to work.

Ketamine can act much faster.

Some research has found meaningful improvement in depressive symptoms within hours, with effects potentially becoming noticeable during the first day of treatment in responsive patients.

This rapid onset is particularly significant for people experiencing treatment-resistant depression.

But speed should not be confused with guaranteed effectiveness.

A patient may respond rapidly to ketamine, respond gradually, experience only partial improvement, or experience no meaningful benefit. Clinical assessment and follow-up remain essential.

Ketamine vs SSRIs: Which Is More Effective?

There is no simple answer because the treatments have different indications, populations, formulations and evidence bases.

SSRIs remain established treatments for many forms of depression and anxiety.

Ketamine and esketamine have attracted particular attention for treatment-resistant depression, where standard treatments have not produced adequate improvement.

NIMH describes treatment-resistant depression as depression that does not improve after trying at least two antidepressants. Esketamine is FDA-approved for treatment-resistant depression in adults.

This distinction matters.

Someone experiencing a first depressive episode may not need ketamine. Another person who has experienced persistent depression despite several adequate treatment attempts may have very different treatment considerations.

In other words:

The question should not simply be “Is ketamine better than an SSRI?”

A better question is:

“Which treatment makes the most sense for this person’s specific clinical situation?”

What Is Treatment-Resistant Depression?

Treatment-resistant depression, often abbreviated TRD, generally refers to depression that has not responded adequately to appropriate treatment attempts.

Definitions can vary across clinical settings, but failure to respond adequately to at least two antidepressant trials is commonly used as an important threshold.

Importantly, not every case of apparent treatment resistance means that the medication itself failed.

Doctors may need to consider:

• Whether the diagnosis is correct
• Whether the medication dose was adequate
• Whether treatment continued long enough
• Whether the medication was taken consistently
• Whether another medical condition is contributing to symptoms
• Whether substance use or other medications are affecting symptoms
• Whether psychotherapy or another treatment should be added
• Whether the person may benefit from a different medication class or treatment approach

This is why a thorough psychiatric assessment is so important before moving to an advanced treatment such as ketamine.

Where Does Spravato Fit Into the Picture?

One of the most important distinctions in the ketamine conversation is the difference between ketamine and esketamine.

Spravato® is the brand name for esketamine nasal spray.

Esketamine is related to ketamine but is not identical to racemic ketamine used in IV treatment.

The FDA currently approves Spravato for:

• Treatment-resistant depression in adults, as monotherapy or with an oral antidepressant
• Depressive symptoms in adults with major depressive disorder accompanied by acute suicidal ideation or behavior, when used with an oral antidepressant

The FDA label also requires administration under healthcare-provider supervision and at least two hours of post-administration monitoring because of risks including sedation, dissociation and respiratory depression.

This is an important reason why Spravato should not be treated as interchangeable with IV ketamine when discussing approval, insurance or clinical use.

IV Ketamine vs Spravato

IV ketamine is widely studied for treatment-resistant depression, but its psychiatric use is generally considered off-label in the United States.

Ketamine itself is FDA-approved as an anesthetic. Its use for depression through IV administration is a different clinical application.

Spravato, on the other hand, is specifically FDA-approved for defined depressive indications.

	IV Ketamine	Spravato® (Esketamine)
Medication	Racemic ketamine	Esketamine
Route	Intravenous infusion	Nasal spray
FDA-approved as antidepressant?	No	Yes, for specific indications
Depression use	Generally off-label	FDA-approved for specified indications
Monitoring	Clinical monitoring required	Healthcare-supervised administration and monitoring
Speed	Rapid in responsive patients	Rapid in responsive patients
Insurance	Coverage varies considerably	More likely to have insurance coverage when criteria are met
Treatment setting	Usually specialized clinical setting	Certified healthcare setting under required monitoring

The distinction is especially important when evaluating ketamine therapy cost and insurance coverage.

---

What Does the Research Say About Ketamine for Depression?

The evidence for ketamine’s antidepressant effects has grown considerably.

NIMH-supported research has helped establish ketamine as an important area of investigation for rapidly acting treatments for treatment-resistant depression.

Research has also compared IV ketamine with established treatments such as electroconvulsive therapy.

In the large ELEKT-D randomized clinical trial, IV ketamine was found to be noninferior to ECT for treatment response in adults with nonpsychotic treatment-resistant major depression. In that study, 55.4% of patients in the ketamine group achieved a response compared with 41.2% in the ECT group during the initial treatment phase. Ketamine was associated with dissociation, while ECT was associated with greater short-term memory effects in the study.

That does not mean ketamine is universally better than ECT—or that it is appropriate for every patient.

It does show why ketamine has become an important treatment option to discuss in carefully selected cases of treatment-resistant depression.

More recent systematic reviews continue to investigate how ketamine compares with ECT and other advanced treatments, while also emphasizing limitations in the evidence and variation among studies.

Ketamine Side Effects vs Antidepressant Side Effects

The side-effect profiles are different.

Common Ketamine-Related Effects

Ketamine treatment can cause:

• Dissociation
• Dizziness
• Drowsiness
• Nausea
• Temporary increases in blood pressure
• Changes in perception
• Headache

Some effects are short-lived, but ketamine also carries important concerns related to misuse and dependence.

The FDA’s prescribing information for Spravato includes boxed warnings related to sedation, dissociation, respiratory depression, abuse and misuse, and requires monitoring after administration.

NIMH research into single-dose IV ketamine has also documented short-lived dissociative and perceptual effects, reinforcing why treatment should be medically supervised.

Common Antidepressant Side Effects

Traditional antidepressants can cause:

• Nausea
• Headache
• Sleep changes
• Appetite changes
• Sexual dysfunction
• Fatigue or activation
• Other medication-specific effects

Stopping some antidepressants too quickly can also cause discontinuation symptoms.

NIMH notes that side effects vary between medications and individuals, and patients should speak with a healthcare professional before starting or stopping psychiatric medication.

Neither treatment category is completely free of risk.

The relevant question is whether the expected benefits outweigh the risks for the individual patient.

---

Does Ketamine Replace Antidepressants?

Not automatically.

Ketamine should not be viewed as a universal replacement for traditional antidepressants.

Some patients may use ketamine or esketamine alongside an oral antidepressant. In other situations, a clinician may consider changing or tapering existing medication as part of an individualized treatment plan.

For Spravato, the FDA’s current labeling specifically allows treatment-resistant depression as monotherapy or in conjunction with an oral antidepressant.

Whether someone should continue, change or stop an antidepressant is a medical decision—not something that should be determined from an online article.

How Long Do Ketamine’s Effects Last?

One of the biggest unanswered questions surrounding ketamine therapy is how to maintain improvement over time.

Ketamine can act rapidly, but the antidepressant effect does not necessarily last indefinitely after a single treatment.

NIMH notes that most people require more than one ketamine treatment session to achieve lasting effects. Research is continuing to examine maintenance schedules and ways of extending therapeutic benefit.

This is another major difference from conventional antidepressants.

SSRIs and SNRIs are generally taken every day to maintain medication exposure. Ketamine-based treatment is usually structured as a series of treatments followed by individualized maintenance or follow-up decisions.

The exact schedule depends on the formulation, diagnosis, clinical response and provider’s treatment protocol.

Is Ketamine Right for Everyone?

No.

Ketamine requires careful medical screening.

A clinician may consider:

• Current psychiatric symptoms
• Previous treatment history
• Cardiovascular health
• Blood pressure
• Current medications
• Substance-use history
• Risk of psychosis or mania
• Pregnancy or breastfeeding considerations
• Previous reactions to ketamine
• Other medical conditions

The FDA prescribing information for Spravato, for example, lists important contraindications and warnings and requires blood-pressure assessment and post-treatment monitoring.

People should never attempt to self-treat depression with ketamine obtained outside appropriate medical care.

Ketamine, Psychotherapy and the Role of Integration

Medication is only one part of depression care.

Psychotherapy can be used alongside medication and other treatments, and NIMH recognizes psychotherapy as a core treatment option for depression.

Research is also exploring whether structured psychological or behavioral interventions can help extend ketamine’s antidepressant effects. One NIMH-supported randomized clinical trial found that brief cognitive training following a ketamine infusion was associated with sustained antidepressant effects over at least 30 days, although further research is needed.

This does not mean every ketamine patient requires ketamine-assisted psychotherapy.

Rather, it highlights an increasingly important concept:

Rapid symptom relief and long-term recovery are not necessarily the same thing.

A comprehensive treatment plan may combine medication, psychotherapy, lifestyle interventions, monitoring and other evidence-based treatments according to the individual’s needs.

Ketamine vs Traditional Antidepressants: Which Should You Choose?

There is no universal winner.

Traditional antidepressants may make sense when:

• You are starting treatment for depression
• You have not yet tried conventional medication
• Your symptoms are responding adequately
• Cost and convenience are important considerations
• Daily medication is appropriate for your situation
• Your clinician recommends an SSRI, SNRI or another antidepressant

Ketamine-based treatment may be considered when:

• Depression has remained significant despite previous treatments
• You meet clinical criteria for treatment-resistant depression
• Rapid symptom improvement is an important consideration
• Your clinician determines that ketamine or esketamine is appropriate
• You understand the monitoring, risks and potential costs
• Conventional treatment has not provided sufficient benefit

Other options may also deserve consideration

Ketamine is not the only treatment available for difficult-to-treat depression.

Depending on the clinical situation, a healthcare professional may discuss:

• Medication changes
• Medication combinations
• Psychotherapy
• Transcranial magnetic stimulation (TMS)
• Electroconvulsive therapy (ECT)
• Esketamine
• Other evidence-based interventions

The goal is not to find the most fashionable treatment.

The goal is to find the safest and most effective treatment strategy for the individual patient.

Ketamine Is Different, Not Simply Better

Ketamine has changed the conversation around depression because it demonstrates something traditional antidepressants do not consistently provide: the possibility of rapid antidepressant effects through a different biological pathway.

Traditional antidepressants such as SSRIs and SNRIs remain valuable, evidence-based treatments for millions of people. They are familiar, accessible and supported by decades of research.

Ketamine offers another pathway—particularly for carefully selected people with treatment-resistant depression.

Its rapid action, glutamate-related mechanism and growing evidence base make it an important development in modern psychiatry. At the same time, ketamine has meaningful safety considerations, its long-term evidence base is still developing, and it should not be presented as a guaranteed cure or a universal replacement for antidepressants.

Frequently Asked Questions About Ketamine vs Antidepressants

Is ketamine better than traditional antidepressants?

Not universally. Ketamine can work much faster than traditional antidepressants in some people and may be particularly useful for treatment-resistant depression. Traditional antidepressants remain appropriate and effective for many people.

How fast does ketamine work compared with antidepressants?

Traditional antidepressants commonly take around 4–8 weeks to work. Ketamine can produce antidepressant effects within hours in some responsive patients. Individual responses vary.

Does ketamine work differently from SSRIs?

Yes. SSRIs primarily affect serotonin signaling, while ketamine’s antidepressant effects involve the glutamate/NMDA system and downstream changes associated with neuroplasticity.

Is ketamine FDA-approved for depression?

Traditional ketamine is FDA-approved as an anesthetic, not as a general antidepressant. However, esketamine nasal spray, sold as Spravato®, is FDA-approved for specific depressive indications, including treatment-resistant depression in adults.

What is the difference between ketamine and Spravato?

Ketamine and esketamine are related but distinct medications. IV ketamine is commonly used off-label for depression, while Spravato is an FDA-approved esketamine nasal spray with specific indications and mandatory supervised administration.

Can ketamine be used after antidepressants fail?

Yes. Ketamine and esketamine are particularly relevant to discussions about treatment-resistant depression. A clinician typically reviews previous treatments, diagnoses, medical history and safety considerations before determining whether treatment is appropriate.

Can ketamine replace an SSRI?

Not necessarily. Some patients may use ketamine-based treatment with an antidepressant, while others may have their medication plan adjusted by their clinician. Never stop or change psychiatric medication without professional guidance.

Does ketamine have side effects?

Yes. Possible effects include dissociation, dizziness, nausea, drowsiness and temporary increases in blood pressure. Ketamine and esketamine also have important warnings concerning sedation, misuse and other risks, which is why appropriate medical supervision matters.

Is ketamine treatment only for severe depression?

Ketamine-based treatments are not appropriate for everyone with depression. Their established role is particularly relevant to treatment-resistant depression, while FDA-approved esketamine has specific indications. A clinician should determine whether a patient is an appropriate candidate.

What should I try first: an antidepressant or ketamine?

That depends on your clinical history. Traditional antidepressants remain an important first-line treatment for many people. Ketamine-based treatment may become a consideration when depression persists despite appropriate conventional treatment or when a clinician identifies another reason it may be suitable.